enhanced inflammatory responses in cell culture and in vivo models of systemic inflammation 11, 12 . These preclinical studies were translated to the clinical setting, where the presence of an APOE4 allele was associated with increased evidence of systemic inflammation following cardiopulmonary bypass and severe sepsis in a surgical intensive care population [13] [14] [15] .
In addition to gaining insight into the dynamic interplay between lipid metabolism and inflammation, a more complete understanding of the role that lipid mediators play in modulating systemic and central nervous system (CNS) inflammatory responses may lead to new therapeutic strategies for the treatment of sepsis. For example, based on evidence that apoE influences key elements of the immune response via receptor-mediated interactions, peptides derived from the receptor binding region of apoE were shown to suppress local and systemic inflammatory responses 11, 12, 16 . (APO: gene; apo: protein). As the APOE3 and APOE4 polymorphisms are most common, in the current study we utilisd targeted replacement mice that express the human APOE3 and APOE4 alleles 17 . These mice have the human APOE locus construct in the correct genetic locus. As they are under the proper control of upstream and downstream regulatory elements, they produce human apoE in physiologically correct spatial and temporal locations within the brain. Northern blot analysis demonstrates the apoE levels in the skin, spleen, kidney, small intestine, heart, testes, muscle, lung, liver and brain were expressed at normal physiological levels when compared to native apoE in wild-type animals 17, 18 .
In the current study, we demonstrate enhanced production of proinflammatory cytokines associated with APOE4 in a murine model of peritonitis induced by caecal ligation and puncture (CLP). In addition, we demonstrate the efficacy of a novel therapeutic strategy for sepsis syndrome using a peptide derived from the receptor binding region of apoE. In this peritonitis model, an apoE-mimetic peptide improved survival and proinflammatory cytokine production in mice with an endogenous murine apoE genetic background, and with the humanised APOE3 or APOE4 genetic background.
MATERIALS AND METHODS

Transgenic animals
All animal experiments were approved by the Duke Institutional Animal Care and Use Committee. Targeted replacement (TR) mice were created by replacing only the coding regions of mouse APOE with human APOE allele-specific coding sequences, without disturbing any known regulatory regions. This procedure results in animals that express human apoE protein at physiological levels in both a temporal and spatial pattern similar to primates and humans 17, 18 . Both APOE3TR and APOE4TR lines were created in an identical fashion and were backcrossed eight generations to a common C57BL6/J genetic background.
Caecal ligation and puncture model
Following induction of anaesthesia with 4.2% isoflurane in an inducing chamber, the mouse trachea was intubated, isoflurane was reduced to 1.6% and the lungs were mechanically ventilated with a 0.7 ml tidal volume at 110 breaths per minute. Rectal temperature was servoregulated at 37.0°C. A 1 cm midline abdominal incision was made and the caecum was isolated and ligated below the ileocaecal valve using 4-0 silk suture. Careful attention was paid to avoid obstruction of the ileum or colon. The caecum was then subjected to a single 'throughand-through' perforation (using an 18-gauge needle) and was slightly compressed until a small drop of stool appeared. The abdominal incision was then closed in layers, the isoflurane was discontinued and the animal was volume resuscitated by subcutaneous injection of 1 ml saline. After recovery of spontaneous ventilation, the mouse was then transferred to a recovery box and the trachea was extubated. All mice were observed for mortality for three days and were then euthanased.
COG1410 synthesis and peptide injections
The COG1410 peptide, acetyl-AS-Aib-LRkL-Aib-kRLL-amide, was synthesised by NeoMPS (San Diego, CA, USA) to a purity of at least 95%. For all in vivo experiments, peptides were dissolved in sterile saline immediately prior to use and were injected into the tail vein at a concentration of 0.6 mg/kg in a volume of 100 µl sterile isotonic saline. The peptide was administered 30 minutes after the CLP procedure and again in 12-hour intervals for 72 hours. Control groups underwent the identical treatment schedule using the sterile isotonic saline vehicle.
Cytokine analysis
Serum samples were obtained from COG1410 or vehicle treated animals at 24 hours post CLP. Mice were anaesthetised with isoflurane and ventilated with 21% oxygen. Blood was then collected by transcardiac puncture and allowed to clot for 30 minutes. Serum samples were centrifuged at 16,000 × g for five minutes, quick-frozen via immersion in liquid nitrogen and stored at -80°C. Quantitation of the serum cytokines was performed using a BioPlex mouse cytokine assay kit (BioSource/Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol with internal standards for quantitation. On the day of analysis, samples were thawed at room temperature for two hours; each sample was run in triplicate.
Statistical analysis
Survival curves were generated by assessing cumulative survival observed in 12-hour intervals over a 72-hour period post-procedure. Survival analyses were assessed using the Mantel and Cox log-rank test, which tests the null hypothesis that no between-group differences in survival exist. Statistical significance was assumed by P <0.05. Cytokine data was assessed by two-way analysis of variance to determine treatment and genetic effects. Post hoc testing was performed with Scheffe's test to correct for multiple comparisons. Statistical significance was assumed with P <0.05. Values are expressed as mean ± standard deviation.
RESULTS
To establish whether APOE polymorphism influences proinflammatory cytokine production and survival in a murine model of sepsis, caecal ligation and puncture was performed on APOE3 (n=22) and APOE4 (n=16) targeted replacement mice, and survival was monitored for 72 hours. Survival curves demonstrated increased mortality in the APOE4TR mice relative to their APOE3TR counterparts (P=0.039; Figure 1 ). Given the difference in survival, a second cohort of APOE4TR (n=10) and APOE3TR (n=10) animals were subjected to caecal ligation and puncture and blood was collected 24 hours following the procedure. Cytokine analysis was performed on the serum from these animals using a 10 cytokine multiplex assay kit ( Table 1) . Production of tumour necrosis factor-alpha (TNFα) was found to be 2.2-fold higher in the APOE4TR animals than in the APOE3TR animals (P=0.11), while interleukin-1ß (IL-1ß) and interleukin-6 (IL-6) increased approximately two-fold higher in the APOE4 animals (P=0.022 for IL-1ß and P=0.027 for IL-6) and interleukin-12 (IL-12) increased 3.5-fold (P=0.007). This is consistent with prior clinical and preclinical data suggesting that the APOE4 allele is associated with enhanced inflammatory responses in vivo as measured by production of proinflammatory cytokines 11, 12 .
Following demonstration that the APOE polymorphisms affect both inflammatory response and survival following caecal ligation and puncture, we determined the ability of a peptide derived from the receptor binding region of apoE, COG1410, to produce an anti-inflammatory effect and reduce mortality in wildtype C57BL6/J mice. In a separate experiment, COG1410 or the sterile isotonic saline vehicle (n=14 animals/group) was given by intravenous administration 30 minutes following the CLP procedure; additional doses were administered at 12-hour intervals. APOE4TR and APOE3TR animals were subjected to caecal ligation and puncture and blood was collected 24 hours following the procedure. Cytokine analysis was performed on the serum from these animals using a ten cytokine multiplex assay kit. The presence of APOE4 was associated with elevations in a number of inflammatory cytokines. IL=interleukin, INF=interferon, GM-CSF=granulocyte-monocyte colony-stimulating factor, TNF=tumour necrosis factor. After monitoring survival for three days, administration of COG1410 was found to significantly reduce mortality when compared to treatment with vehicle alone (P=0.02; Figure 2 ).
To assess whether there was a pharmacogenomic interaction between the therapeutic effect of the apoE peptide and the humanised APOE background, COG1410 or vehicle was administered in the identical dosing paradigm to APOE3TR (n=20 animals/group) and APOE4TR mice (n=16 animals/ group). COG1410 was found to significantly reduce mortality in both the APOE3TR (P=0.007 in treated vs. untreated) and APOE4TR (P=0.027 in treated vs. untreated; Figure 3 ). Notably, cumulative survival increased to 20% in COG1410-treated animals from both the APOE4TR and APOE3TR groups, as compared to 0% and 5% survival in the vehicle-treated APOE4TR and APOE3TR mice, respectively.
Previous data suggest that apoE might influence systemic inflammatory responses by exerting isoformspecific anti-inflammatory effects. To address this potential mechanism, we measured pro-inflammatory cytokine levels in COG1410-treated and untreated APOE3TR and APOE4TR animals (n=5/group) at 24 hours following the caecal ligation and puncture procedure (Figure 4 ). IL-6, a representative proinflammatory cytokine, was significantly increased in APOE4 animals as compared to the APOE3 counterparts (5268.3±707 vs. 2444.4±924 pg/ml P=0.027). Treatment with COG1410 significantly reduced IL-6 levels in both APOE3TR (303.8±29.7 vs. 2444.4±924 pg/ml in treated vs. untreated animals; P=0.03) and APOE4TR animals (2934.2±867 vs. 5268.3±707.2 pg/ml in treated vs. untreated animals; P=0.05; Figure 4A ). Serum levels of TNFα significantly declined as a function of treatment with COG1410 in the APOE4TR animals (72.1±24.6 vs. 196.8±52.2 pg/ml in treated vs. untreated animals; P=0.04), although this effect did not reach significance in the APOE3TR animals (86.6±39.4 vs. 14.7±4.4 pg/ ml in treated vs. untreated animals; P=0.07; Figure  4B ). Likewise, administration of COG1410 reduced IL-1ß levels in APOE3TR (3.2±2.1 vs. 23.1 pg/ml ±7.2; P=0.02 in treated vs. untreated animals) and APOE4TR (25.2±9.4 vs. 40.2±8.4 pg/ml in treated vs. untreated animals; P=0.2; Figure 4C ).
Recent evidence has also implicated IL-12 in modifying neutrophil function and mortality in the murine peritonitis model 19, 20 , as well as influencing clinical outcome following sepsis 21 . We found that serum IL-12 levels were significantly Figure 4D ).
When taken together, these results demonstrate a primary genetic influence of APOE on inflammation, as the presence of the APOE4 allele is associated with higher mortality rates and increased levels of inflammatory cytokines as compared to APOE3. Therapeutic administration of the apoE peptide COG1410 was associated with reduced inflammatory cytokines and improved mortality in both APOE3TR and APOE4TR animals.
DISCUSSION
In the current study, we demonstrate that the APOE4 polymorphism is associated with an increased inflammatory response and higher rates of mortality in a murine model of caecal ligation and puncture. Although the majority of research examining genetic influences on sepsis focuses on classical inflammatory mediators, there is an expanding body of literature which suggests a dynamic interplay between lipid metabolism and systemic inflammation. In particular, several recent observations have implicated a role 
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Vehicle COG1410 * Figure 4 : A separate cohort of mice (n=5 animals/group) was sacrificed at 24 hours following the CLP procedure, and serum was collected for cytokine analysis. A) Interleukin-6 levels were significantly reduced in APOE3TR mice as compared to APOE4TR mice (*P <0.05). Treatment with COG1410 administered following CLP and at 12 hours post-CLP was associated with significant reductions in serum IL-6 in both APOE3TR and APOE4TR animals (*P <0.05). B) TNFα levels were lower in APOE4TR animals as compared to APOE3TR animals, and was also reduced as a function of COG1410 treatment in both genetic lines (*P <0.05). C) Serum IL-1ß levels were reduced in APOE4TR as compared to APOE3TR animals; treatment with COG1410 reduced IL-1ß in both APOE3TR and APOE4TR lines. D) APOE4TR animals had significantly higher levels of serum IL-12 as compared to their APOE3TR counterparts. Intravenous administration of COG1410 at 12 hour intervals significantly reduced serum IL-12 levels in both APOE3TR and APOE4TR groups (data expressed as mean ± SD; *P <0.05; ANOVA).
A D C B for apoE in modulating systemic 8, 22 and CNS 12, 23 inflammatory responses. ApoE deficient animals have impaired immunity after bacterial challenge, as well as increased susceptibility to endotoxaemia following intravenous lipopolysaccharide (LPS) administration 24, 25 . ApoE deficient animals have also been reported to have an increased systemic inflammatory responses 23 and higher mortality rates following LPS injection 26 . Furthermore, administration of exogenous apoE improved mortality via downregulation of the inflammatory cascade 26 .
One of the strengths of the current study is that we utilised targeted replacement mice which were created by replacing only the coding regions of mouse APOE with human APOE allele-specific coding sequences, without disturbing any known regulatory regions. This procedure results in animals that express human apoE protein at physiological levels in both a temporal and spatial pattern similar to primates and humans. Indeed, this targeted replacement resulted in mice that express human apoE mRNA with a similar tissue distribution and levels to that of mouse apoE mRNA in wild type animals 17, 18 . Genotype effects of apoE on disease progression are well established for a number of conditions, including Alzheimer's disease, where patients carrying the APOE4 allele experience an earlier onset and more rapid progression than patients that lack the APOE4 allele 27 . Inflammation appears to be a common element in each of the disorders that have a demonstrated apoE genotype effect, which may be attributed to isoform-specific differences of apoE's modulation of inflammatory responses. For example, we have recently demonstrated that mice expressing the human APOE4 gene have enhanced systemic and CNS inflammatory responses following LPS injection, as compared to their APOE3 counterparts 12 . These preclinical studies demonstrating isoformspecific differences in the immunomodulatory properties of apoE have recently been extended to human populations. For example, patients possessing the APOE4 gene demonstrate an increased inflammatory response following cardiopulmonary bypass [13] [14] [15] , which may in part explain the increase in neurological morbidity in this patient population 28 . Moreover, the presence of the APOE4 allele has recently been associated with an increased risk of sepsis following elective surgical procedures 29 . The enhanced CNS inflammatory response in the setting of systemic inflammation may also be related to the fact that critically ill patients possessing the APOE4 allele are more likely to suffer from enhanced neuroinflammatory responses associated with acute delirium, a finding that is independently associated with poor outcome in the critically ill 30 .
Our results are consistent with a growing body of literature suggesting that cholesterol metabolism plays a critical role in modulating systemic inflammatory responses 31, 32 . In particular, apoE4 is preferentially found in very low density lipoprotein particles. In contrast, the apoE3 isoform is found primarily in high-density lipoprotein (HDL), which has been found to have immunomodulatory properties in a variety of experimental paradigms 33, 34 . One mechanism by which HDL exerts these antiinflammatory effects is by direct interaction and neutralisation of LPS 35, 36 . However, accumulating data suggests alternative mechanisms of HDL action which are dependent on direct cell surface interactions. For example, binding of HDL to the scavenger receptor BI has been shown to initiate adaptive stress responses, including the induction of eNOS expression and the activation of Akt and mitogen-activated protein kinases 37 . The direct immunomodulatory effects of HDL constituents have led to the strategy of developing therapeutic apolipoprotein mimetic peptides. For example, an apoA-1 mimetic peptide has been found to reduce inflammatory responses in vitro and in vivo 38 . While the mechanism(s) by which apoE modify systemic and CNS inflammatory responses remain poorly defined, insight may be found in recent studies demonstrating that microglia derived from APOE4TR mice have altered cell morphology, increased NO production (accompanied by increased NOS2 mRNA levels), and enhanced cytokine production (TNFα, IL-6, IL12) compared to microglia derived from APOE3TR mice 39 .
There are several limitations to the current study which should be addressed. Although the use of targeted replacement animals represents a powerful tool for studying the isoform-specific effects of apoE, care should be taken when extrapolating murine data to the human population. While murine caecal ligation and puncture is an imperfect model of clinical polymicrobial sepsis, it has been used widely and replicates many aspects of sepsis including an extended time course of bacteraemia and robust inflammatory response with production of TNFα, IL-1ß, IL-6 and IL-12 that match the human clinical syndrome 40 . In the current study, COG1410 was administered at 12-hour intervals. This dosing regimen has proven successful in a model of delayed cerebral ischaemia following aneurysmal subarachnoid haemorrhage 41 and is consistent with the short serum half-life of COG1410 42 , although the optimal timing and dosing regimen would need to be defined prior to clinical translation. Moreover, although we demonstrate statistically significant differences in mortality and inflammatory mediators as a function of APOE genotype and treatment with the apoE peptide, these differences were relatively modest and do not necessarily imply clinical relevance. The current study is also somewhat limited by the absence of long-term outcome data and the fact that each cytokine may display differential kinetics following CLP. Although a complete time course of the different cytokine levels is beyond the scope of our current study, our data suggest that at the 24 hour time point, APOE polymorphism modifies the inflammatory cascade.
In addition to providing insight regarding the interaction between lipid metabolism and inflammation, a more complete understanding of the role that apolipoprotein E plays in modulating inflammatory responses may lead to new therapeutic strategies for the treatment of sepsis. Consistent with this hypothesis, COG133, a peptide derived from the receptor binding region of apoE (positions 133 to 149), initiates a signaling cascade in immunocompetent cells and reduces inflammatory cytokine release in microglial culture 43 . This apoE derived peptide crosses the blood brain barrier 42 and reduces both systemic and CNS inflammatory responses in a murine model of systemic inflammation and head injury 12, 42 . Based on rational structure-function considerations, COG1410 was designed as a shorter analogue of the receptor binding region of apoE (positions 138 to 149) with aminoisobutyric acid substitutions at positions 140 and 145 inserted to stabilise the helical nature of this region and promote receptor interactions. COG1410 possesses many of the same properties as COG133, but is superior due to its enhanced anti-inflammatory efficacy and potency in vitro 16, 42 .
Consistent with earlier published studies, we observed that APOE4TR animals produce an enhanced inflammatory response relative to APOE3TR animals, as demonstrated by the two-to four-fold increased cytokine production observed in this study. Furthermore, the APOE4TR animals demonstrated a more rapid progression of systemic inflammation, which was associated with increased early mortality. Although administration of apoE derived peptides show promise as a therapeutic approach, the current preclinical paradigm was somewhat artificial, as animals received the first dose within 30 minutes following surgery. In clinical practice, it is often difficult to initiate treatment early in the course of sepsis. However, the current data are consistent with a growing body of clinical and preclinical evidence suggesting that apoE is a biologically relevant mediator of the inflammatory response, and may affect systemic inflammation in an isoform-specific fashion.
